Nav: Home

Refuting the idea that mutations cause cancer

July 31, 2017

What causes cancer? Smoking, certainly, and also things like sun and chemical exposure. Cancer risk also increases with some genetic predispositions and in old age. One thread connecting these risks is genetic mutations in the cells of our bodies - smoking and UV exposure increase the rate of DNA damage and with each replication of damaged DNA comes the chance of picking up a random mutation that can kickstart cancer. And the longer we live, the more chance that awful luck will result in one of these random, cancer-causing mutations. This is the mutation accumulation theory of oncogenesis: "Cancers are caused by mutations that may be inherited, induced by environmental factors, or result from DNA replication error," write John Hopkins University biostatisticians Tomasetti, Li and Vogelstein in the March 24, 2017 issue of the journal Science.

But there is a parallel thread through these causes of cancer that reaches a much different endpoint. This is the thread of the microenvironment - the ecosystem of the body's tissues. Age and exposures like smoking and UV radiation damage the body's tissues. Writing today in the journal Cancer Research, James DeGregori, PhD, deputy director of the University of Colorado Cancer Center offers evidence that it is forces of evolution driven by natural selection acting in the ecosystem of the body that, in the presence of tissue damage, allow cells with dangerous mutations to thrive. This evolutionary theory of cancer points out that cells containing dangerous mutations exist all the time, but are commonly out-competed by healthy cells that are optimized to live in healthy tissue. It is only when the tissue microenvironment is degraded (by smoking, sun, chemical exposure, age, etc.) that cells with these mutations find themselves most fit and suddenly able to out-compete healthy cells and so establish themselves in the landscape of the body. Mutations are still required for cancers, but changes in our tissues as we age or engage in activities like smoking are the primary determinants of "who gets cancer, how cancer risk relates to known causes, which tissues it occurs in, and when the cancers develop in life," DeGregori writes.

There are a couple ways to visualize this theory. One is with dandelions in a lawn - dandelion seeds are omnipresent, but a healthy lawn keeps them from growing; however, dandelions are poised to take advantage of disturbed earth, quickly invading areas of damage. (In our comparison, seeds are like genetic mutations - they always exist and it is the conditions of the ecosystem that decide whether or not they grow.) Another way to visualize the evolutionary theory of cancer is with the meteor that ended the reign of the dinosaurs - the meteor's dramatic restructuring of the Earth's ecosystems rendered dinosaurs less fit and also stimulated the evolution of many new species including a variety of mammalian species. Environmental change promotes speciation. A similar process in our tissues can lead to what is essentially a new cellular species - cancer.

"We're all loaded with mutations and yet we're not all getting cancer. Why?" DeGregori asks. His answer: "Healthy cells are optimized for healthy tissue. Most mutations make cells less fit. This means that in a healthy tissue microenvironment, healthy cells out-compete pre-cancer cells, keeping these pre-cancer cells in check. But when the tissue microenvironment is damaged, the existing cells with dangerous mutations may now be able to thrive."

A piece of DeGregori's argument rests in the fact that cancer rates do not match mutation rates. He points out that humans will hold about half their lifetime complement of mutations by young adulthood (at which point cells relax the frantic pace of replication used to build the adult body). However, the likelihood of developing cancer does not match this rate of mutation - despite having half of the lifespan's mutations, young adults have much less than half of the lifespan's cancer risk.

DeGregori also shows that along with mismatching the number of mutations in cells, cancer risk also mismatches the number of cells in tissue. According to Tomasetti and colleagues, more cells and more replication should lead to more chance mutations and eventually to more cancer (the more copies, the more chances for the printer to smudge). However, across species this is not true - a blue whale has about 7 million times more cells than a mouse and yet the whale has no more cancer risk across its lifespan. Researchers refer to this as Peto's Paradox.

DeGregori points out that the mismatch between mutational burden and cancer risk is vividly demonstrated by mice with a genetic malfunction that leads to dramatically increased mutation rate (an error in a specific DNA proofreading function). In these mice, many more mutations lead to no increase in cancer rates. It is not the presence of mutations nor the rate at which mutations occur that drive the timing and incidence of cancer.

Work by DeGregori and others has also shown that cancer-causing mutations often make cells less fit. Cells in our tissues are close to "just right" for healthy young tissues; cancer-causing mutations can disrupt this adaptation, leading to cells that are no longer optimized to their surroundings and eventually leading to elimination of mutant cells from the tissue. That is unless disruption of the tissue in old age or following carcinogenic exposures adjusts the surroundings in ways that make these same mutations advantageous.

In all, "Lifetime mutation accumulation in stem cells cannot explain varying cancer predisposition across tissues and species. Instead, we need to consider how aging or carcinogens change tissue microenvironments to increase selection for particular oncogenic mutations," DeGregori writes.

One implication of this line of thought is that research into cancer prevention has been approaching the disease from the wrong angle. If the field believes that mutations are the major factor causing cancer, then preventing cancer depends on preventing mutations. However, if the field looks through DeGregori's lens of evolutionary competition between cancer cells and healthy cells, dependent on their relative adaptation to microenvironments, then preventing cancer depends on maintaining a tissue ecosystem that favors healthy cells.

He points out that studies aimed at restoring or maintaining "a tissue microenvironment that better approached that of a young healthy individual," have been shown to disfavor cancer cells.

"We are not going to anytime soon come up with technologies to prevent most mutations. But manipulating the microenvironment? That's more approachable," DeGregori says.
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.